CML Multimedia

Article

VIDEOS


Dr. Sonali Smith discusses the newest developments in the treatment of CML.


Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors

Roman Fabbricatore
September 18th 2025
Article
Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Gathering the Latest Multidisciplinary Care Insights Across World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mehmet Asim Bilen, MD;Sid Sadler;Kerry R. Schaffer, MD;Mark T. Fleming, MD;Jeff Yorio, MD;Mike Lattanzi, MD;Elizabeth Kessler, MD;Benjamin L. Maughan, MD, PharmD;Alan Tan, MD
September 18th 2025
Podcast
Additional time is necessary to confirm the depth and durability of responses observed in the phase 1 CAMMA 1 study.

Cevostamab Combo Shows Enduring Responses in R/R Multiple Myeloma

Ashling Wahner
September 18th 2025
Article
Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 18th 2025
Podcast
When is Nivolumab/Relatlimab Therapy Viable in BRAF+ Melanoma?

When is Nivolumab/Relatlimab Therapy Viable in BRAF+ Melanoma?

Ariana Pelosci
September 18th 2025
Article
Responses observed with the elranatamab-based regimen in the MagnetisMM-6 trial are anticipated to deepen with longer follow-up.

Elranatamab Combo Yields Early Efficacy in Transplant-Ineligible NDMM

Russ Conroy
September 18th 2025
Article